Dear Public Service Director:
Melanoma is the deadliest form of skin cancer and one of the most common cancers in women under 40. The incidence of melanoma has increased in recent decades, making it one of the fastest growing cancers.[i] In fact, melanoma is the third most commonly diagnosed cancer among young adults (15-39) in the United States[ii]. The Melanoma Research Alliance (MRA), the leading private funder of melanoma research believes it’s essential to educate the public, particularly young women, about melanoma and how they can protect their skin, their beauty, and their life.
To address the rise in melanoma, MRA, in conjunction with L’Oréal Paris, is supporting the It’s THAT Worth It To Me™ public health awareness campaign. This call to action urges women of all skin tones to prevent melanoma by using sunscreen and to help save lives by supporting cutting-edge research for a cure. It is part of a three-year partnership in which L’Oréal Paris is donating $750,000 to MRA to help find a cure through the funding of the new L’Oréal Paris-MRA Team Science Award, led by internationally renowned cancer researcher Meenhard Herlyn, D.V.M., D.Sc., The Wistar Institute, Philadelphia, Pa.
This year’s campaign taps into the star power of Eva Longoria, Aimee Mullins and skin cancer survivor Diane Keaton, all of whom are featured in public service announcements as advocates for this cause. In addition, the campaign features a PSA from a young melanoma survivor and L’Oréal Paris executive Danielle Macaluso, who was diagnosed with melanoma at age 30. Her powerful story helps showcase the importance of sun protection, especially among young women.
Your station can help make an impact by supporting the It’s THAT Worth It To Me™ campaign by sharing these important PSAs with your viewers. In addition, your audience can visit ItsTHATworthit.org for more information.
We hope you can share this important campaign with your audience and help rally the public around stopping melanoma through prevention and research.
Thank you for your consideration.
Melanoma Research Alliance
FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE EMAIL: PSAS@multivu.com